SPRO Stock Price, Spero Therapeutics Inc Quote, Chart

Market Summary

USD1.58+0.01

Market Closed

0.64%

SPRO Stock Price

View Fullscreen

SPRO RSI Chart

SPRO Valuation

Market Cap

85.3M

Price/Earnings (Trailing)

3.64

Price/Sales (Trailing)

0.77

Price/Free Cashflow

-6.01

SPRO Price/Sales (Trailing)

SPRO Profitability

Return on Equity

24.32%

Return on Assets

13.96%

Free Cashflow Yield

-16.65%

SPRO Fundamentals

SPRO Revenue

Revenue (TTM)

111.0M

Rev. Growth (Yr)

347.9%

Rev. Growth (Qtr)

-87.4%

SPRO Earnings

Earnings (TTM)

23.4M

Earnings Growth (Yr)

4.5%

Earnings Growth (Qtr)

-124.75%

Breaking Down SPRO Revenue

Last 7 days

-3.7%

Last 30 days

5.3%

Last 90 days

3.3%

Trailing 12 Months

-12.2%

How does SPRO drawdown profile look like?

SPRO Financial Health

Current Ratio

3.35

SPRO Investor Care

Shares Dilution (1Y)

2.69%

Diluted EPS (TTM)

0.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	111.0M	0	0	0
2023	53.5M	54.2M	77.7M	103.8M
2022	13.0M	9.9M	8.8M	53.5M
2021	14.9M	18.4M	17.4M	18.3M
2020	12.1M	11.7M	11.1M	9.3M
2019	10.5M	12.2M	16.2M	18.1M
2018	3.0M	3.2M	3.3M	4.0M
2017	663.7K	992.3K	1.3M	2.0M
2016	0	0	0	335.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Spero Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 05, 2024	shukla sath	sold	-65,384	1.45	-45,093	ceo and president
Feb 02, 2024	shukla sath	sold	-42,334	1.37	-30,901	ceo and president
Feb 02, 2024	joseph tamara l	sold	-42,341	1.37	-30,906	chief legal officer
Feb 02, 2024	hamed kamal	sold	-38,462	1.37	-28,075	chief medical officer
Feb 02, 2024	mahadevia ankit	sold	-87,399	1.37	-63,795	-
Feb 02, 2024	keutzer timothy	sold	-42,120	1.36	-30,971	chief operating officer
Feb 01, 2024	hamed kamal	acquired	-	-	239,731	chief medical officer
Feb 01, 2024	rajavelu esther	acquired	-	-	119,866	see remarks
Feb 01, 2024	joseph tamara l	acquired	-	-	239,731	chief legal officer
Feb 01, 2024	keutzer timothy	acquired	-	-	239,731	chief operating officer

Which funds bought or sold SPRO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Murchinson Ltd.	added	1.3	234,956	1,503,120	0.13%
May 16, 2024	AWM Investment Company, Inc.	unchanged	-	83,350	573,448	0.07%
May 15, 2024	Man Group plc	new	-	368,125	368,125	-%
May 15, 2024	STATE STREET CORP	unchanged	-	32,628	224,479	-%
May 15, 2024	MORGAN STANLEY	reduced	-34.37	-4,105	13,586	-%
May 15, 2024	AMERIPRISE FINANCIAL INC	sold off	-100	-592,356	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-9.7	478	8,930	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	104	104	-%
May 15, 2024	ADAR1 Capital Management, LLC	reduced	-13.19	24,783	1,594,320	0.36%
May 15, 2024	Shay Capital LLC	new	-	527,983	527,983	0.08%

Are Funds Buying or Selling SPRO?

Are funds buying SPRO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SPRO

No. of Funds

Unveiling Spero Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	anson funds management lp	8.1%	4,297,599	SC 13G
Feb 14, 2023	biotechnology value fund l p	-	0	SC 13G/A
Feb 14, 2023	aquilo capital management, llc	0%	0	SC 13G/A
Jan 20, 2023	gsk plc	17.75%	9,190,606	SC 13D/A
Nov 14, 2022	gsk plc	19.99%	9,190,606	SC 13D/A
Oct 03, 2022	aquilo capital management, llc	3.6%	1,242,965	SC 13G/A
Jul 08, 2022	blackrock inc.	2.1%	690,753	SC 13G
Mar 09, 2022	aquilo capital management, llc	5.1%	1,642,655	SC 13G/A
Feb 14, 2022	aquilo capital management, llc	10.5%	3,378,881	SC 13G/A
Feb 14, 2022	biotechnology value fund l p	6.4%	2,169,102	SC 13G/A

Recent SEC filings of Spero Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
Apr 16, 2024	DEFA14A	DEFA14A
Apr 16, 2024	DEF 14A	DEF 14A
Apr 16, 2024	ARS	ARS
Mar 29, 2024	8-K	Current Report
Mar 22, 2024	EFFECT	EFFECT
Mar 20, 2024	UPLOAD	UPLOAD
Mar 20, 2024	CORRESP	CORRESP
Mar 15, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to Spero Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Spero Therapeutics Inc News

Latest updates

Spero Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-87.4%	9,267,000	73,522,500	25,473,000	2,716,000	2,069,000	47,441,000	2,006,000	1,993,000	2,069,000	2,744,000	3,064,000	5,148,000	7,300,000	1,907,000	3,995,000	1,727,000	1,701,000	3,630,000	4,643,000	2,156,000	7,718,000
Operating Expenses	1.1%	23,249,000	22,990,500	27,407,000	15,606,000	16,296,000	21,517,000	13,840,000	28,073,000	32,276,000	30,246,000	25,588,000	23,690,000	26,703,000	20,703,000	23,015,000	20,203,000	24,522,000	29,513,000	22,628,000	15,808,000	13,414,000
S&GA Expenses	-100.0%	-	6,433,000	5,708,000	6,096,000	7,317,000	6,495,000	6,632,000	8,051,000	15,305,000	13,021,000	11,152,000	9,229,000	8,299,000	7,498,000	5,309,000	4,547,000	4,086,000	3,785,000	4,133,000	3,782,000	3,888,000
R&D Expenses	4.7%	17,332,000	16,557,500	16,393,000	9,510,000	8,979,000	15,089,000	7,360,000	8,173,000	16,971,000	17,225,000	14,436,000	14,461,000	18,404,000	13,205,000	17,706,000	15,656,000	20,436,000	25,728,000	18,495,000	12,026,000	9,526,000
EBITDA Margin	-	-	-	-	-	-	-	-	-9.02	-6.84	-4.88	-	-	-5.19	-8.30	-5.47	-5.14	-4.96	-3.31	-2.51	-3.36	-3.91
Income Taxes	-100.0%	-	387,000	2,200,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-	-	-	-	-	-	-	-	-9.09	-6.89	-4.92	-	-	-5.24	-8.39	-5.51	-5.21	-5.02	-3.36	-2.57	-3.41	-3.96
Net Income	-124.7%	-12,669,000	51,191,000	-3,205,000	-11,914,000	-13,266,000	26,771,000	-11,675,000	-28,682,000	-32,829,000	-29,240,000	-22,521,000	-18,572,000	-19,423,000	-18,585,000	-18,936,000	-17,501,000	-23,258,000	-24,986,000	-17,717,000	-13,150,000	-5,072,000
Net Income Margin	-4.0%	0.21	0.22	-0.02	-0.19	-0.50	-0.87	-11.62	-11.48	-7.92	-4.92	-4.54	-4.12	-	-	-	-	-	-	-	-	-
Free Cashflow	133.9%	5,938,000	-17,493,000	15,915,000	-18,564,000	-12,853,000	44,482,000	-957,000	-23,033,000	-28,223,000	-27,349,000	-4,952,000	-16,579,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-8.1%	168	182	107	99.00	113	125	64.00	64.00	146	171	145	120	143	153	157	98.00	110	106	113	122	125
Current Assets	6.8%	140	131	102	88.00	102	114	53.00	52.00	133	158	132	106	129	139	143	85.00	98.00	95.00	104	113	116
Cash Equivalents	7.8%	82.00	76.00	94.00	78.00	96.00	109	50.00	45.00	72.00	113	113	72.00	77.00	85.00	125	65.00	64.00	30.00	46.00	71.00	49.00
Net PPE	0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00
Liabilities	-5.4%	71.00	75.00	53.00	44.00	48.00	49.00	32.00	28.00	83.00	83.00	33.00	29.00	25.00	21.00	24.00	24.00	27.00	32.00	19.00	13.00	11.00
Current Liabilities	12.6%	42.00	37.00	25.00	17.00	23.00	22.00	16.00	14.00	69.00	19.00	17.00	13.00	18.00	14.00	18.00	19.00	23.00	27.00	15.00	8.00	7.00
Shareholder's Equity	-10.0%	96.00	107	54.00	55.00	65.00	76.00	32.00	36.00	62.00	88.00	112	90.00	119	132	133	74.00	82.00	75.00	93.00	110	113
Retained Earnings	-3.2%	-403	-391	-442	-439	-427	-413	-440	-428	-400	-367	-338	-315	-297	-277	-259	-240	-222	-199	-174	-156	-143
Additional Paid-In Capital	0.4%	500	498	496	494	492	490	473	465	463	456	450	406	416	410	392	314	305	274	267	266	257
Shares Outstanding	1.6%	54.00	53.00	53.00	53.00	53.00	52.00	36.00	33.00	33.00	32.00	30.00	30.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00
Float	-	-	-	-	76.00	-	22.00	-	-	-	-	-	326	-	-	-	256	-	-	-	151	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	133.9%	5,938	-17,493	15,915	-18,564	-12,853	44,482	-957	-23,033	-28,223	-27,349	-4,952	-16,567	-15,479	-16,383	-21,264	-24,896	-23,329	-17,367	-9,659	-12,070	-10,924
Share Based Compensation	1.3%	2,023	1,997	1,908	1,857	2,170	2,497	2,106	1,317	3,203	2,928	2,330	2,163	2,009	1,365	1,199	1,214	1,110	929	981	933	933
Cashflow From Investing	-	-	-	-	-	-	-	-129	50,000	-16,064	-23,275	17,025	10,919	3,003	-39,740	3,949	18,485	27,776	-4,099	-15,887	24,845	24,671
Cashflow From Financing	-100.0%	-	1.00	220	-	-	14,179	6,131	-53,677	3,814	50,349	29,224	168	4,309	16,090	77,215	7,390	30,186	5,599	10.00	8,963	1,568

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SPRO Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Grant revenue	$ 5,063	$ 1,329
Collaboration revenue - related party	4,064	517
Collaboration revenue	$ 140	$ 223
Type of Revenue [Extensible List]	us-gaap:LicenseMember	us-gaap:LicenseMember
Total revenues	$ 9,267	$ 2,069
Operating expenses:
Research and development	17,332	8,979
General and administrative	5,917	7,317
Total operating expenses	23,249	16,296
Loss from operations	(13,982)	(14,227)
Other income (expense):
Interest income	1,327	963
Other income (expense), net	(14)	(2)
Total other income (expense), net	1,313	961
Net loss and comprehensive loss	$ (12,669)	$ (13,266)
Net loss per share attributable to common stockholders, basic	$ (0.24)	$ (0.25)
Net loss per share attributable to common stockholders, diluted	$ (0.24)	$ (0.25)
Weighted average common shares outstanding, basic	53,524,037	52,527,018
Weighted average common shares outstanding, diluted	53,524,037	52,527,018

SPRO Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 82,271	$ 76,333
Collaboration receivable, current - related party	49,198	49,152
Other receivables	5,017	1,545
Prepaid expenses and other current assets	3,668	4,178
Total current assets	140,154	131,208
Property and equipment, net	2	2
Operating lease right of use assets	3,902	4,155
Collaboration receivable, non-current - related party	23,211	46,590
Other assets	434	435
Total assets	167,703	182,390
Current liabilities:
Accounts payable	3,066	1,378
Accrued expenses and other current liabilities	5,380	6,557
Operating lease liabilities	1,725	1,718
Income taxes payable	387	387
Deferred revenue, current	2,868	2,132
Deferred revenue, current - related party	28,395	24,981
Total current liabilities	41,821	37,153
Non-current operating lease liabilities	3,519	3,825
Deferred revenue, non-current	9,948	10,825
Deferred revenue, non-current - related party	16,128	23,606
Other long-term liabilities	38	87
Total liabilities	71,454	75,496
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 53,869,139 shares issued and outstanding as of March 31, 2024 and 52,999,680 shares issued and outstanding as of December 31, 2023	54	53
Additional paid-in capital	499,936	497,913
Accumulated deficit	(403,741)	(391,072)
Total stockholders' equity	96,249	106,894
Total liabilities and stockholders' equity	$ 167,703	$ 182,390

About Spero Therapeutics Inc

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Satyavrat Shukla C.F.A.
WEBSITE	https://sperotherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	35

Spero Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Spero Therapeutics Inc? What does SPRO stand for in stocks?

SPRO is the stock ticker symbol of Spero Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Spero Therapeutics Inc (SPRO)?

As of Fri May 17 2024, market cap of Spero Therapeutics Inc is 85.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SPRO stock?

You can check SPRO's fair value in chart for subscribers.

What is the fair value of SPRO stock?

You can check SPRO's fair value in chart for subscribers. The fair value of Spero Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Spero Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SPRO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Spero Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SPRO is over valued or under valued. Whether Spero Therapeutics Inc is cheap or expensive depends on the assumptions which impact Spero Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SPRO.

What is Spero Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SPRO's PE ratio (Price to Earnings) is 3.64 and Price to Sales (PS) ratio is 0.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SPRO PE ratio will change depending on the future growth rate expectations of investors.